Literature DB >> 33934277

Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues.

Shinya Sato1,2, Satoshi Maki3, Takashi Yamanaka4, Daisuke Hoshino5, Yukihide Ota6, Emi Yoshioka7, Kae Kawachi7, Kota Washimi7, Masaki Suzuki7, Yoichiro Ohkubo7, Tomoyuki Yokose7, Toshinari Yamashita4, Seiji Ohtori3, Yohei Miyagi6.   

Abstract

PURPOSE: Diagnosis of breast preneoplastic and neoplastic lesions is difficult due to their similar morphology in breast biopsy specimens. To diagnose these lesions, pathologists perform immunohistochemical analysis and consult with expert breast pathologists. These additional examinations are time-consuming and expensive. Artificial intelligence (AI)-based image analysis has recently improved, and may help in ordinal pathological diagnosis. Here, we showed the significance of machine learning-based image analysis of breast preneoplastic and neoplastic lesions for facilitating high-throughput diagnosis.
METHODS: Images were obtained from normal mammary glands, hyperplastic lesions, preneoplastic lesions and neoplastic lesions, such as usual ductal hyperplasia (UDH), columnar cell lesion (CCL), ductal carcinoma in situ (DCIS), and DCIS with comedo necrosis (comedo DCIS) in breast biopsy specimens. The original enhanced convoluted neural network (CNN) system was used for analyzing the pathological images.
RESULTS: The AI-based image analysis provided the following area under the curve values (AUC): normal lesion versus DCIS, 0.9902; DCIS versus comedo DCIS, 0.9942; normal lesion versus CCL, 0.9786; and UDH versus DCIS, 1.000. Multiple comparison analysis showed precision and recall scores similar to those of single comparison analysis. Based on the gradient-weighted class activation mapping (Grad-CAM) used to visualize the important regions reflecting the result of CNN analysis, the ratio of stromal tissue in the whole weighted area was significantly higher in UDH and CCL than that in DCIS.
CONCLUSIONS: These analyses may provide a more accurate and rapid pathological diagnosis of patients. Moreover, Grad-CAM identifies uncharted important histological characteristics for newer pathological findings and targets of research for understanding diseases.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Artificial intelligence; Breast cancer; Grad-CAM; Machine learning; Pathological diagnosis; Preneoplastic and neoplastic lesions

Mesh:

Year:  2021        PMID: 33934277     DOI: 10.1007/s10549-021-06243-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  47 in total

1.  Automated complete slide digitization: a medium for simultaneous viewing by multiple pathologists.

Authors:  F J Leong; J O McGee
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

Review 2.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

3.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

4.  Assessment of "grading" with Ki-67 and c-kit immunohistochemical expressions may be a helpful tool in management of patients with flat epithelial atypia (FEA) and columnar cell lesions (CCLs) on core breast biopsy.

Authors:  Rosa M Tomasino; Vincenza Morello; Arianna Gullo; Giancarlo Pompei; Valentina Agnese; Antonio Russo; Gaetana Rinaldi
Journal:  J Cell Physiol       Date:  2009-11       Impact factor: 6.384

5.  Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.

Authors:  Lynn J Howie; Harpreet Singh; Erik Bloomquist; Suparna Wedam; Laleh Amiri-Kordestani; Shenghui Tang; Rajeshwari Sridhara; Jacqueline Sanchez; Tatiana M Prowell; Paul G Kluetz; Belinda L King-Kallimanis; Jennifer J Gao; Amna Ibrahim; Kirsten B Goldberg; Marc Theoret; Richard Pazdur; Julia A Beaver
Journal:  J Clin Oncol       Date:  2019-09-27       Impact factor: 44.544

Review 6.  Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.

Authors:  Mohammad H Forouzanfar; Kyle J Foreman; Allyne M Delossantos; Rafael Lozano; Alan D Lopez; Christopher J L Murray; Mohsen Naghavi
Journal:  Lancet       Date:  2011-09-14       Impact factor: 79.321

7.  Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Authors:  M Martín; S Loibl; T Hyslop; J De la Haba-Rodríguez; B Aktas; C T Cirrincione; K Mehta; W T Barry; S Morales; L A Carey; J A Garcia-Saenz; A Partridge; N Martinez-Jañez; O Hahn; E Winer; A Guerrero-Zotano; C Hudis; M Casas; C Rodriguez-Martin; J Furlanetto; E Carrasco; M N Dickler
Journal:  Eur J Cancer       Date:  2019-07-02       Impact factor: 9.162

8.  Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast.

Authors:  Werner Boecker; Göran Stenman; Tina Schroeder; Udo Schumacher; Thomas Loening; Lisa Stahnke; Catharina Löhnert; Robert Michael Siering; Arthur Kuper; Vera Samoilova; Markus Tiemann; Eberhard Korsching; Igor Buchwalow
Journal:  Virchows Arch       Date:  2017-03-16       Impact factor: 4.064

9.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors:  Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

10.  Discrepancies in the diagnosis of intraductal proliferative lesions of the breast and its management implications: results of a multinational survey.

Authors:  Mohiedean Ghofrani; Beatriz Tapia; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2006-10-13       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.